-
公开(公告)号:US10945994B2
公开(公告)日:2021-03-16
申请号:US15573190
申请日:2016-05-12
Applicant: Pfizer Inc. , iTeos Therapeutics
Inventor: Manfred Kraus , Sandra Cauwenberghs , Stefano Crosignani , Gregory Driessens
IPC: A61K31/404 , A61K39/395 , A61P35/00 , A61K45/06 , A61K31/519 , A61K31/53 , A61K31/495 , A61P31/12 , A61P15/00 , A61K31/337 , C07K16/28 , A61K9/00 , A61K39/00
Abstract: Combinations of an IDO1 inhibitor (e.g., a 3-(5-fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione compound), with an anti-PD1 antibody or anti-PD-L1 antibody, and an anti-4-1BB antibody, as selected anti-cancer or anti-viral agents are provided. Also provided are use of these combinations for the treatment and/or prevention of cancer and endometriosis.
-
公开(公告)号:US10881321B2
公开(公告)日:2021-01-05
申请号:US15229594
申请日:2016-08-05
Inventor: Ragini Verma , Birkan Tunc
IPC: A61B5/00 , A61B5/055 , G01R33/563
Abstract: Method and apparatus for processing diffusion data for identification of white matter tracts in the brain of a patient is provided herein. The method involves, with a processor: generating a connectivity based representation of white matter fibers for multiple different subjects from the connectivity signatures of the fibers from a diffusion magnetic resonance imaging (dMRI) without using the physical coordinates of the fibers; generating a fiber bundle atlas from the connectivity based fiber representation of (a) which define a model of the human brain; adaptively clustering fibers of a new patient utilizing the fiber bundle atlas of (b) to extract white matter tracts without manual intervention in the form of drawing regions of interest; and presenting the selected white matter tracts and diffusion data in a report or on a display device. This method and apparatus can be used even for patients having edema or brain perturbations.
-
公开(公告)号:US10544095B2
公开(公告)日:2020-01-28
申请号:US15749963
申请日:2016-08-04
Applicant: Pfizer Inc. , iTeos Therapeutics
Inventor: Sacha Ninkovic , Michael Raymond Collins , Stefano Crosignani , Andreas Maderna , Indrawan James McAlpine , Stephanie Anne Scales , Martin Wythes
IPC: A61K31/404 , C07D209/10 , C07D209/18 , C07D403/12 , C07D403/14 , C07D409/12 , C07D413/12 , A61P25/28 , A61P35/02 , A61P25/24 , A61P25/16 , C07D401/12 , C07D401/14 , C07D403/10 , C07D405/12
Abstract: A compound of Formula I is provided: or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also relates to a process for manufacturing compounds of Formula I.
-
公开(公告)号:US10392622B2
公开(公告)日:2019-08-27
申请号:US15500591
申请日:2015-07-31
Inventor: Mitchell Lewis , Jean Bennett , Luk Vandenberghe , Matthew Sochor , Theodore G. Drivas
IPC: C12N15/63
Abstract: A self-regulating gene expression construct comprises a single promoter in operative association with a repressor sequence (e.g., bacterial repressor lacI or gaiR), operator sequence(s) responsive to the expressed repressor protein, and a transgene. A dual-regulating construct comprises a single promoter controlling expression of a bacterial repressor sequence and a transgene, and which, in the presence of a first inducer molecule, transcribes the transgene and repressor; and a ribozyme in association with an aptamer sequence, the aptamer sequence capable of interacting with a second inducer molecule to terminate mRNA degradation by the ribozyme. Also provided are recombinant vectors or viruses containing the self-regulating or dual self-regulating constructs and cells containing the vectors. Such compositions are useful in methods of treating a diseases using gene therapy.
-
公开(公告)号:US10137176B2
公开(公告)日:2018-11-27
申请号:US14769596
申请日:2014-03-13
Inventor: James M. Wilson , Brittney L. Gurda
Abstract: A vector having an expression cassette having a hIDUA gene having a sequence of SEQ ID NO: 1 or a sequence at least about 95% identical thereto which encodes a functional human alpha-L-iduronidase is provided. The vector may be production vector or a rAAV8. Also provided are compositions containing these vectors and methods of treating MPSI and the symptoms associated with Hurler, Hurle-Scheie and Scheie syndromes.
-
公开(公告)号:US10086087B2
公开(公告)日:2018-10-02
申请号:US15619637
申请日:2017-06-12
Applicant: Tris Pharma, Inc.
Inventor: Ketan Mehta , Yu-Hsing Tu
IPC: A61K47/32 , A61K31/135 , A61K31/137 , A61K31/155 , A61K31/192 , A61K31/216 , A61K31/24 , A61K31/4402 , A61K31/4458 , A61K31/485 , A61K45/06 , A61K47/14 , A61K9/00 , A61K9/10 , A61K9/14 , A61K9/16 , A61K9/20 , A61K9/48 , A61K9/50 , A61K47/58 , A61K47/69
Abstract: A particulate, modified release barrier coated drug-cation exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. Methods of making and products containing this coated complex are described.
-
公开(公告)号:US09867797B2
公开(公告)日:2018-01-16
申请号:US15075697
申请日:2016-03-21
Applicant: TRIS Pharma Inc.
Inventor: Andrea Nelson , Quin-Zene Chen , Harsh Mehta , Yu-Hsing Tu
IPC: A61K9/22 , A61K31/245 , A61K31/25 , A61K31/09 , A61K9/20 , A61K9/24 , A61K9/28 , A61K45/06 , A61K9/00 , A61K9/50
CPC classification number: A61K31/245 , A61K9/0053 , A61K9/2009 , A61K9/2013 , A61K9/2054 , A61K9/2077 , A61K9/2081 , A61K9/209 , A61K9/2846 , A61K9/2866 , A61K9/2886 , A61K9/5084 , A61K31/09 , A61K31/25 , A61K45/06 , A61K2300/00
Abstract: A 12-hour anti-tussive modified release solid tablet or capsule is described which comprises a benzonatate adsorbate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a 12-hour modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay.
-
公开(公告)号:US11253612B2
公开(公告)日:2022-02-22
申请号:US16093413
申请日:2017-04-14
Inventor: Christian Hinderer , James M. Wilson
IPC: A61K48/00 , A61P3/00 , C12N15/113 , C12N15/85 , C12N9/16 , C12Q1/6827 , C12N15/86
Abstract: A suspension useful for AAV9-mediated intrathecal and/or systemic delivery of an expression cassette containing a hIDS gene is provided herein. Also provided are methods and kits containing these vectors and compositions useful for treating Hunter syndrome and the symptoms associated with Hunter syndrome.
-
公开(公告)号:US11028372B2
公开(公告)日:2021-06-08
申请号:US16060404
申请日:2016-12-09
Inventor: Martin Lock , Mauricio Alvira
IPC: C12N7/02 , C12N7/00 , B01D15/38 , B01J20/281 , C12N15/864 , G01N21/33 , B01J41/05 , B01D15/16 , B01D15/36 , B01J41/20
Abstract: A two-step chromatography purification scheme is described which selectively captures and isolates the genome-containing rAAV vector particles from the clarified, concentrated supernatant of a rAAV production cell culture. The process utilizes an affinity capture method performed at a high salt concentration followed by an anion exchange resin method performed at high pH to provide rAAV vector particles which are substantially free of rAAV intermediates.
-
公开(公告)号:US10975140B2
公开(公告)日:2021-04-13
申请号:US16821295
申请日:2020-03-17
Inventor: James M. Wilson , Anna Tretiakova
Abstract: A recombinant adeno-associated virus (AAV) having an AAV capsid and packaged therein a heterologous nucleic acid which expresses two functional antibody constructs in a cell is described. Also described are antibodies comprising a heavy chain and a light chain from a heterologous antibody. In one embodiment, the antibodies are co-expressed from a vector containing: a first expression cassette which encodes at least a first open reading frame (ORF) for a first immunoglobulin under the control of regulatory control sequences which direct expression thereof; and a second expression cassette which comprises a second ORF, a linker, and a third ORF under the control of regulatory control sequences which direct expression thereof, wherein the second and third ORF for a second and third immunoglobulin construct. The vector co-expressing these two antibody constructs is in one embodiment an AAV, in which the 5′ and 3′ ITRs flank the expression cassettes and regulatory sequences.
-
-
-
-
-
-
-
-
-